| Market Cap | 1.06B | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -93.73M | Forward P/E | -8.69 | EPS next Y | - | 50D Avg Chg | 6.00% |
| Sales | 27.34M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 63.00% |
| Dividend | N/A | Price/Book | 4.95 | EPS next 5Y | 16.50% | 52W High Chg | -1.00% |
| Recommedations | 3.00 | Quick Ratio | 9.00 | Shares Outstanding | 62.81M | 52W Low Chg | 296.00% |
| Insider Own | 4.50% | ROA | -25.87% | Shares Float | 31.09M | Beta | 0.10 |
| Inst Own | 83.80% | ROE | -56.92% | Shares Shorted/Prior | 77.60K/580.30K | Price | 16.85 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 1,168,169 | Target Price | 18.33 |
| Oper. Margin | -294.52% | Earnings Date | Apr 19 | Volume | 130,404 | Change | 0.00% |
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
| Credit Suisse | Outperform | May 4, 21 |
| B of A Securities | Buy | May 4, 21 |
| SVB Leerink | Outperform | May 4, 21 |